5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond
July 2006
in “
European Urology Supplements
”
Studysummary 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on sciencedirect.com →